Key facts
- This page summarizes Paul Herendeen's Form 4 filing for Elanco Animal Health Inc (ELAN).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 26 May 2026, 16:46.
Paul Herendeen - 21 May 2026 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)
- Reporting relationship
- Director
- Issuer ticker
- ELAN
- Reported as of
- 21 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 May 2026, 16:46:09 UTC
- Prior SEC filing
- 02 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy C. Seidel, as Attorney-in-Fact for Paul Herendeen
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Paul Herendeen filed Form 4 for Elanco Animal Health Inc (ELAN) on 26 May 2026.
Change
- Previous filing in this sequence was filed on 02 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001374175
Primary reporting owner
Herendeen Paul
- Relationship
- Director
- Address
- C/O ELANCO ANIMAL HEALTH INCORPORATED, 450 ELANCO CIRCLE, INDIANAPOLIS
- Signature
- /s/ Amy C. Seidel, as Attorney-in-Fact for Paul Herendeen
- Signature date
- 26 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELAN
transaction
Common Stock
Award
- Transaction value
- Shares
- +4,678
- Change %
- +5.5%
- Price
- $0.000000*
- Shares after
- 89,491
- Date
- 21 May 2026
- Ownership
- Direct
- Footnotes
- F1
ELAN
transaction
Common Stock
Award
- Transaction value
- Shares
- +12,196
- Change %
- +14%
- Price
- $0.000000*
- Shares after
- 101,687
- Date
- 21 May 2026
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.
Footnote F2
Grant of restricted stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.